Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Swedish Orphan Biovitrum AB is an international biopharmaceutical company headquartered in Stockholm, Sweden, specializing in treatments for rare diseases within haematology, immunology, and specialty care. It focuses on researching, developing, manufacturing, and commercializing innovative therapies for conditions such as haemophilia, immune thrombocytopenia (ITP), cryopyrin-associated periodic syndromes (CAPS), respiratory syncytial virus (RSV) in infants, and hemophagocytic lymphohistiocytosis (HLH). Key products include Elocta and Alprolix for haemophilia, Doptelet for ITP and chronic liver disease, Kineret for autoinflammatory disorders, Synagis for RSV prevention, and Gamifant for primary HLH. The company maintains a robust pipeline with investigational therapies targeting paroxysmal nocturnal hemoglobinuria (PNH), secondary HLH, acute graft failure, ALS, chronic refractory gout, and notably pozdeutinurad (AR882) for gout following the 2025 acquisition of Arthrosi Therapeutics. Originating from mergers in the early 2000s and the 2010 acquisition of Swedish Orphan International, Swedish Orphan Biovitrum AB plays a vital role in addressing unmet needs in orphan and specialty medicines, serving patients globally through partnerships and its own operations.
kr 460.10
kr 7.00 (-1.50%)
Live · 05:20 PM · Twelve Data
Operating margin is thin at 3.27%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue grew 8.5%, steady but not accelerating. Margins contracted 18.3pp, which offsets some of the top-line progress.
At 176x earnings, the current multiple leaves limited room for execution misses or growth deceleration. ROIC dropped from 8.88% to 1.74%, capital efficiency is deteriorating.
175.6x earnings, 40.2x FCF. The market is pricing in years of above-average growth. If that thesis breaks, downside from multiple compression alone could be 30%+. This is a stock where you're paying for the future, not the present.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 28.96B
▲ +8.5% YoY
Net Income (TTM)
kr 919M
▼ -87.7% YoY
Op. Margin
4.94%
▼ -18.3pp YoY
ROIC
1.74%
▼ -7.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
kr 4.00B
▲ +23.5% YoY
Op. Cash Flow (TTM)
kr 5.06B
▼ -2.1% YoY
Net Debt
kr 10.45B
Cash & Equiv.
kr 1.04B
3Y CAGR: +14.5%
3Y CAGR: +20.4%
Continue Research
At a P/E of 175.6 and a price-to-free-cash-flow of 40.2, Swedish Orphan Biovitrum AB (SOBI.XSTO) trades above a two-stage DCF intrinsic value of about SEK 168.49 per share, so at SEK 460.10 the stock looks overvalued (63.4% above estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Swedish Orphan Biovitrum AB scores 36/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about SEK 168.49 per share for SOBI.XSTO, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around SEK 126.37. At today's SEK 460.10, that puts the stock about 63.4% above estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Swedish Orphan Biovitrum AB scores 36 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a 4.9% operating margin and a 1.7% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. SOBI.XSTO currently trades above its estimated intrinsic value and scores 36/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.